DE602007009957D1 - Neue kristalline form von lamivudin - Google Patents

Neue kristalline form von lamivudin

Info

Publication number
DE602007009957D1
DE602007009957D1 DE602007009957T DE602007009957T DE602007009957D1 DE 602007009957 D1 DE602007009957 D1 DE 602007009957D1 DE 602007009957 T DE602007009957 T DE 602007009957T DE 602007009957 T DE602007009957 T DE 602007009957T DE 602007009957 D1 DE602007009957 D1 DE 602007009957D1
Authority
DE
Germany
Prior art keywords
new
disclosed
pharmaceutical composition
same
lamivudin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007009957T
Other languages
English (en)
Inventor
Girij Pal Singh
Dhananjai Srivastava
Manmeet Brijkishore Saini
Pritesh Rameshbhai Upadhyay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Ltd
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of DE602007009957D1 publication Critical patent/DE602007009957D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE602007009957T 2006-04-18 2007-02-09 Neue kristalline form von lamivudin Active DE602007009957D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN347KO2006 2006-04-18
PCT/IN2007/000047 WO2007119248A1 (en) 2006-04-18 2007-02-09 A novel crystalline form of lamivudine

Publications (1)

Publication Number Publication Date
DE602007009957D1 true DE602007009957D1 (de) 2010-12-02

Family

ID=37969898

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007009957T Active DE602007009957D1 (de) 2006-04-18 2007-02-09 Neue kristalline form von lamivudin

Country Status (10)

Country Link
US (1) US8158607B2 (de)
EP (1) EP2007758B1 (de)
JP (1) JP5184511B2 (de)
AT (1) ATE485292T1 (de)
AU (1) AU2007237818B2 (de)
CA (1) CA2649796A1 (de)
DE (1) DE602007009957D1 (de)
ES (1) ES2357159T3 (de)
WO (1) WO2007119248A1 (de)
ZA (1) ZA200809820B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009037538A2 (en) * 2007-09-17 2009-03-26 Aurobindo Pharma Ltd Process for the preparation of lamivudine form i
WO2009069014A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Amorphous lamivudine and its preparation
CN101918393A (zh) * 2007-11-29 2010-12-15 兰贝克赛实验室有限公司 拉米夫定的晶形i及其制备方法
WO2009116055A1 (en) * 2008-03-17 2009-09-24 Lupin Limited Lamivudine : zidovudine : water 1 : 1 : 1 cocrystal
WO2009127996A1 (en) * 2008-04-17 2009-10-22 Ranbaxy Laboratories Limited Novel crystalline form of lamivudine
WO2010023676A2 (en) 2008-09-01 2010-03-04 Hetero Research Foundation Process for preparing lamivudine polymorph form
US8481554B2 (en) 2009-05-27 2013-07-09 Hetero Research Foundation Solid oral dosage forms of lamivudine
DK2488516T3 (en) 2009-10-14 2015-05-26 Mylan Lab Ltd Method of producing lamivudine and novel salts in the preparation thereof
US8796452B2 (en) 2010-02-12 2014-08-05 Merck Sharp & Dohme Corp. Preparation of lamivudine form I
WO2013168066A1 (en) 2012-05-05 2013-11-14 Lupin Limited An improved process for the manufacture of lamivudine form i.
JP2016507569A (ja) * 2013-02-07 2016-03-10 トビラ セラピューティクス， インコーポレイテッド ラミブジン結晶塩

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
WO2003027106A1 (en) * 2001-09-25 2003-04-03 Cadila Healthcar Limited Process for the preparation of crystalline polymorph ii of lamivudine

Also Published As

Publication number Publication date
JP5184511B2 (ja) 2013-04-17
ZA200809820B (en) 2010-02-24
AU2007237818A1 (en) 2007-10-25
US8158607B2 (en) 2012-04-17
ATE485292T1 (de) 2010-11-15
EP2007758A1 (de) 2008-12-31
ES2357159T3 (es) 2011-04-19
EP2007758B1 (de) 2010-10-20
CA2649796A1 (en) 2007-10-25
AU2007237818B2 (en) 2012-09-27
US20090281053A1 (en) 2009-11-12
JP2009534373A (ja) 2009-09-24
WO2007119248A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
ATE485292T1 (de) Neue kristalline form von lamivudin
MY167135A (en) Fused heterocyclic derivatives and methods of use
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
MX2009006764A (es) Pirimidinonas biciclicas y usos de la misma.
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
EA200802203A1 (ru) Дикетопиперазиновые и пиперидиновые производные в качестве противовирусных агентов
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
JO3271B1 (ar) مشتقات الكوينولين المضادة للجراثيم
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
CL2007003609A1 (es) Compuestos derivados de dihidropiridinas sustituidas; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; proceso para producir la composicion farmaceutica; y uso en el tratamiento de una enfermedad mejorada con la inhibicion
CL2008003067A1 (es) Compuesto 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)-[1,2,4]triazol-1-il]-n-etil-acetamida, modulador de receptores nicotinicos alfa-7; proceso de preparacion; composicion farmaceutica y su proceso de preparacion; y su uso en el tratamiento de trastornos psicoticos, intelectuales, inflamatorios.
SG10201501376XA (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
ME01456B (me) Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola
EA200970534A1 (ru) Антибактериальные производные хинолина
WO2009042094A3 (en) Hiv protease inhibitors
MX2009007040A (es) Derivados de mononitrato de isosorbida para el tratamiento de hipertension ocular.
HK1137431A1 (en) Antibacterial quinoline derivatives
CL2007003318A1 (es) Compuestos derivados de 4,5-difenil-pirrol-2-carboxamida; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento o la prevencion de enfermedades tales como sindrome de abstinencia a una sustancia, t
TW200640933A (en) Anthelmintic compounds
EA200970536A1 (ru) Антибактериальные хинолиновые производные
PE20080550A1 (es) Sal xinafoato del etil ester de la 1-[[5-(1(s)-aminoetil)-2-[8-metoxi-2-(trifluorometil)-5-quinolil]-4-oxazolil]carbonil]-4(r)-[(ciclopropil-carbonil)amino]-l-prolina
JO2685B1 (en) Quinoline antibacterial derivatives
UY31896A (es) Derivados de 5-(4-metanosulfonil-fenil)-tiazol para el tratamiento de enfermedades inflamatorias agudas y crónicas